Journal
NATURE MEDICINE
Volume 16, Issue 3, Pages 319-U116Publisher
NATURE PUBLISHING GROUP
DOI: 10.1038/nm.2089
Keywords
-
Funding
- US National Institutes of Health (NIH) AIDS Research and Reference Reagent Program
- NIH [AI058727, AI066305, AI066924, AI078526, AI084794, RR000168, AI067854, AI061734]
- Los Alamos National Laboratory
Ask authors/readers for more resources
The worldwide diversity of HIV-1 presents an unprecedented challenge for vaccine development(1,2). Antigens derived from natural HIV-1 sequences have elicited only a limited breadth of cellular immune responses in nonhuman primate studies and clinical trials to date. Polyvalent 'mosaic' antigens, in contrast, are designed to optimize cellular immunologic coverage of global HIV-1 sequence diversity(3). Here we show that mosaic HIV-1 Gag, Pol and Env antigens expressed by recombinant, replication-incompetent adenovirus serotype 26 vectors markedly augmented both the breadth and depth without compromising the magnitude of antigen-specific T lymphocyte responses as compared with consensus or natural sequence HIV-1 antigens in rhesus monkeys. Polyvalent mosaic antigens therefore represent a promising strategy to expand cellular immunologic vaccine coverage for genetically diverse pathogens such as HIV-1.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available